Career history of Po-Shun Lee
Former positions of Po-Shun Lee
Companies | Position | Start | End |
---|---|---|---|
PROTEOSTASIS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2014-10-31 | 2019-07-21 |
VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 2010-07-31 | 2012-12-31 |
Critical Biologics Corp.
Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA. | Founder | 2009-12-17 | - |
Training of Po-Shun Lee
University of Pennsylvania | Doctorate Degree |
The Johns Hopkins University | Undergraduate Degree |
Statistics
International
United States | 6 |
Operational
Founder | 1 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
Private companies | 2 |
---|---|
Critical Biologics Corp.
Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA. | Health Technology |
Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Po-Shun Lee
- Experience